What research findings exist for Survodutide in weight loss and weight management?
Obesity combined with diabetes In adults with diabetes at 76 weeks, weight loss was better than placebo. Another study reported that the proportion of weight loss and reaching the weight loss threshold in Survodutide group was better than placebo.[1] ↗ [2] ↗
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42820639 | Human Phase III randomized; SYNCHRONIZE-2 | Obesity combined with diabetes in adults with diabetes lost weight at 76 weeks compared to placebo. | Limited trial populations and formulations. |
| 2026 · PMID 42253238 | 725 non-diabetic obese/overweight adults; 76-week SYNCHRONIZE-1 Phase III randomized trial. | The Survodutide study group had a higher proportion of weight loss and achievement of weight reduction thresholds than placebo. | Experimental Formulation Combined with Lifestyle Counseling; Gastrointestinal Reactions Common, Cannot Be Simply Ranked Against Other Experimental Statistical Goals or Populations. |
| 2024 · PMID 38330987 | 386 treated overweight/obese adults without diabetes; 46-week Phase II randomized trial | The study shows weight loss in dosage groups is better than placebo, supporting direct weight management research. | Completion rate is about 60%, with planned dosage and actual maintenance dose analysis differing; Do not mix different estimated results or provide bottled usage. |
References
What findings do Survodutide studies on obesity combined with diabetes show?
Obesity combined with diabetes in adults with diabetes lost weight at 76 weeks compared to placebo.[1] ↗
Human Phase III randomized; SYNCHRONIZE-2
Limited trial populations and formulations.
View the Article Title and Full Citation＋
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
The New England Journal of Medicine · Volume, Issue, Year 2026
First published 2026-10-01 · PMID 42820639
DOI 10.1056/nejmoa2607219
What are the results of Phase III weight loss in non-diabetic obese adults?
The Survodutide study group had a higher proportion of weight loss and achievement of weight reduction thresholds than placebo.[2] ↗
725 non-diabetic obese/overweight adults; 76-week SYNCHRONIZE-1 Phase III randomized trial.
Experimental Formulation Combined with Lifestyle Counseling; Gastrointestinal Reactions Common, Cannot Be Simply Ranked Against Other Experimental Statistical Goals or Populations.
View the Article Title and Full Citation＋
Survodutide Once Weekly for the Treatment of Adults with Obesity.
The New England Journal of Medicine · Volume, Issue, Year 2026
First published 2026-06-07 · PMID 42253238
DOI 10.1056/NEJMoa2600751
46 weeks Survodutide dose exploration—what does it indicate?
The study shows weight loss in dosage groups is better than placebo, supporting direct weight management research.[3] ↗
386 treated overweight/obese adults without diabetes; 46-week Phase II randomized trial
Completion rate is about 60%, with planned dosage and actual maintenance dose analysis differing; Do not mix different estimated results or provide bottled usage.
View the Article Title and Full Citation＋
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
The Lancet. Diabetes & Endocrinology · Volume and issue year 2024
First published 2024-02-05 · PMID 38330987
DOI 10.1016/S2213-8587(23)00356-X
Common issues and corresponding evidence
What research findings exist for Survodutide in weight loss and weight management?＋
Obesity combined with diabetes In adults with diabetes at 76 weeks, weight loss was better than placebo. Another study reported that the proportion of weight loss and reaching the weight loss threshold in Survodutide group was better than placebo.[1] ↗ [2] ↗
Can weight loss results for populations with and without diabetes be directly combined for comparison?＋
Not suitable. The two phase III trials of Survodutide were conducted in populations with and without diabetes, respectively. Weight results should be understood according to the enrollment criteria, follow-up, and statistical objectives of each trial, and the percentages from different trials should not be simply ranked.[1] ↗ [2] ↗
Survodutide—these conclusions apply to which study populations?＋
Human Phase III randomized; SYNCHRONIZE-2; 725 non-diabetic obese/overweight adults; 76-week SYNCHRONIZE-1 Phase III randomized trial; 386 treated non-diabetic overweight/obese adults; 46-week Phase II randomized trial. Limited trial populations and formulations.[1] ↗ [2] ↗ [3] ↗
Survodutide
Return to catalog specifications and batch file verification entry.
